Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

2.

Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Abgueguen P, Azoulay-Dupuis E, Noel V, Moine P, Rieux V, Fantin B, Bedos JP.

Antimicrob Agents Chemother. 2007 Jan;51(1):208-14. Epub 2006 Oct 23.

3.

Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Azoulay-Dupuis E, Mohler J, Bédos JP, Barau C, Fantin B.

Antimicrob Agents Chemother. 2006 Sep;50(9):3033-8.

4.

Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T.

Antimicrob Agents Chemother. 2005 Mar;49(3):1046-54.

5.

Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.

Azoulay-Dupuis E, Bédos JP, Mohler J, Schmitt-Hoffmann A, Schleimer M, Shapiro S.

Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11.

6.

Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Azoulay-Dupuis E, Bédos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Péchère JC, Fantin B, Köhler T.

Antimicrob Agents Chemother. 2004 Mar;48(3):765-73.

7.

Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.

Azoulay-Dupuis E, Mohler J, Bédos JP.

Antimicrob Agents Chemother. 2004 Jan;48(1):80-5.

8.

Streptococcus pneumoniae strain-dependent lung inflammatory responses in a murine model of pneumococcal pneumonia.

Mohler J, Azoulay-Dupuis E, Amory-Rivier C, Mazoit JX, Bédos JP, Rieux V, Moine P.

Intensive Care Med. 2003 May;29(5):808-16. Epub 2003 Mar 29.

PMID:
12665994
9.

Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae.

Rieux V, Carbon C, Azoulay-Dupuis E.

J Infect Dis. 2001 Jul 1;184(1):66-72. Epub 2001 Jun 8.

PMID:
11398111
10.

Nuclear factor-kappaB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection.

Amory-Rivier CF, Mohler J, Bédos JP, Azoulay-Dupuis E, Henin D, Muffat-Joly M, Carbon C, Moine P.

Crit Care Med. 2000 Sep;28(9):3249-56.

PMID:
11008989
11.

Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Azoulay-Dupuis E, Rieux V, Muffat-Joly M, Bédos JP, Vallée E, Rivier C, Isturiz R, Carbon C, Moine P.

Antimicrob Agents Chemother. 2000 Jun;44(6):1575-7.

12.

[Selection of virulent mutants of Streptococcus pneumoniae. Utilization of a murine model of septicemia].

Amory-Rivier C, Rieux V, Azoulay-Dupuis E, Carbon C, Trombe MC.

Pathol Biol (Paris). 1999 May;47(5):519-25. French.

PMID:
10418032
13.

[Current microbiologic problems. Pulmonary infection by Streptococcus pneumoniae. Current physiopathological aspects].

Bédos JP, Rivier C, Azoulay-Dupuis E, Moine P.

Presse Med. 1999 Feb 27;28(8):442-9. Review. French.

PMID:
10093606
14.
15.

Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.

Bédos JP, Azoulay-Dupuis E, Moine P, Muffat-Joly M, Veber B, Pocidalo JJ, Vallée E.

J Pharmacol Exp Ther. 1998 Jul;286(1):29-35.

PMID:
9655838
16.

Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Bédos JP, Rieux V, Bauchet J, Muffat-Joly M, Carbon C, Azoulay-Dupuis E.

Antimicrob Agents Chemother. 1998 Apr;42(4):862-7.

17.

Western blot analysis of antibody response to pneumococcal protein antigens in a murine model of pneumonia.

Mouneimne H, Juvin M, Beretti JL, Azoulay-Dupuis E, Vallee E, Geslin P, Petitpretz P, Berche P, Gaillard JL.

Clin Diagn Lab Immunol. 1997 Nov;4(6):778-82.

19.

Correlation between in vitro and in vivo activity of amoxicillin against Streptococcus pneumoniae in a murine pneumonia model.

Moine P, Mazoit JX, Bédos JP, Vallée E, Azoulay-Dupuis E.

J Pharmacol Exp Ther. 1997 Jan;280(1):310-5.

PMID:
8996211
20.

Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.

Sauve C, Azoulay-Dupuis E, Moine P, Darras-Joly C, Rieux V, Carbon C, Bédos JP.

Antimicrob Agents Chemother. 1996 Dec;40(12):2829-34.

21.

Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.

Darras-Joly C, Bédos JP, Sauve C, Moine P, Vallée E, Carbon C, Azoulay-Dupuis E.

Antimicrob Agents Chemother. 1996 Sep;40(9):2147-51.

23.

In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Moine P, Vallée E, Azoulay-Dupuis E, Bourget P, Bédos JP, Bauchet J, Pocidalo JJ.

Antimicrob Agents Chemother. 1994 Sep;38(9):1953-8.

24.

Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia.

Veber B, Vallée E, Desmonts JM, Pocidalo JJ, Azoulay-Dupuis E.

J Antimicrob Chemother. 1993 Sep;32(3):473-82.

PMID:
8262870
25.
26.

Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.

Vallée E, Azoulay-Dupuis E, Bauchet J, Pocidalo JJ.

J Pharmacol Exp Ther. 1992 Sep;262(3):1203-8.

PMID:
1326627
27.

Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection.

Vallée E, Azoulay-Dupuis E, Pocidalo JJ, Bergogne-Bérézin E.

Antimicrob Agents Chemother. 1992 Jul;36(7):1412-7.

28.

Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse.

Bédos JP, Azoulay-Dupuis E, Vallée E, Veber B, Pocidalo JJ.

J Antimicrob Chemother. 1992 Jun;29(6):677-85.

PMID:
1387132
29.

Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin.

Azoulay-Dupuis E, Bedos JP, Vallée E, Pocidalo JJ.

J Antimicrob Chemother. 1991 Dec;28 Suppl C:45-53.

PMID:
1664829
30.

Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.

Vallée E, Azoulay-Dupuis E, Pocidalo JJ, Bergogne-Bérézin E.

J Antimicrob Chemother. 1991 Dec;28 Suppl C:39-44.

PMID:
1664828
31.

Delayed lymphoid lung infiltration induced by cyclophosphamide in rats.

Lurie A, Bernaudin JF, Theven D, Brun-Pascaud M, Azoulay-Dupuis E, Soler P, Pocidalo JJ.

Methods Find Exp Clin Pharmacol. 1991 Jul-Aug;13(6):405-11.

PMID:
1881200
32.

Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.

Azoulay-Dupuis E, Vallée E, Bedos JP, Muffat-Joly M, Pocidalo JJ.

Antimicrob Agents Chemother. 1991 Jun;35(6):1024-8.

33.

Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

Azoulay-Dupuis E, Bedos JP, Vallée E, Hardy DJ, Swanson RN, Pocidalo JJ.

J Infect Dis. 1991 Feb;163(2):319-24.

PMID:
1988515
34.

Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.

Vallée E, Azoulay-Dupuis E, Swanson R, Bergogne-Bérézin E, Pocidalo JJ.

J Antimicrob Chemother. 1991 Feb;27 Suppl A:31-41.

PMID:
1827100
35.

Genetic differences in response to pulmonary cytochrome P-450 inducers and oxygen toxicity.

Mansour H, Levacher M, Azoulay-Dupuis E, Moreau J, Marquetty C, Gougerot-Pocidalo MA.

J Appl Physiol (1985). 1988 Apr;64(4):1376-81.

PMID:
3378972
36.

Protective effect of beta-naphthoflavone against NO2 toxicity in mice with genetically inducible lung cytochrome P450.

Azoulay-Dupuis E, Mansour H, Moreau J, Lachia L.

Toxicol Appl Pharmacol. 1988 Apr;93(2):220-30.

PMID:
3358260
37.

Evidence for humoral immunodepression in NO2-exposed mice: influence of food restriction and stress.

Azoulay-Dupuis E, Bouley G, Moreau J, Muffat-Joly M, Pocidalo JJ.

Environ Res. 1987 Apr;42(2):446-54.

PMID:
3569184
38.

In vivo nitrogen dioxide exposure depresses spleen cell in vitro mitogenic responses: effects of sulfur compounds.

Azoulay-Dupuis E, Gougerot-Pocidalo MA, Kraus L, Moreau J.

Environ Res. 1987 Feb;42(1):130-9.

PMID:
3803331
39.

Impaired acquired resistance of mice to Klebsiella pneumoniae infection induced by acute NO2 exposure.

Bouley G, Azoulay-Dupuis E, Gaudebout C.

Environ Res. 1986 Dec;41(2):497-504.

PMID:
3536476
40.

Humoral immunodepression following acute NO2 exposure in normal and adrenalectomized mice.

Azoulay-Dupuis E, Levacher M, Muffat-Joly M, Pocidalo JJ.

J Toxicol Environ Health. 1985;15(1):149-62.

PMID:
3981662
41.

Lung alterations in guinea-pigs infected with influenza virus.

Azoulay-Dupuis E, Lambre CR, Soler P, Moreau J, Thibon M.

J Comp Pathol. 1984 Apr;94(2):273-83.

PMID:
6330181
42.

Pulmonary NO2 toxicity in neonate and adult guinea pigs and rats.

Azoulay-Dupuis E, Torres M, Soler P, Moreau J.

Environ Res. 1983 Apr;30(2):322-39.

PMID:
6832118
43.

Respiratory effects of normobaric oxygen toxicity in awake guinea-pig.

Pocidalo JJ, Brun-Pascaud M, Blayo MC, Azoulay-Dupuis E.

Comp Biochem Physiol B. 1983;74(4):831-6.

PMID:
6861478
44.

Effects of sulfur dioxide on resistance to bacterial infection in mice.

Azoulay-Dupuis E, Bouley G, Blayo MC.

Environ Res. 1982 Dec;29(2):312-9. No abstract available.

PMID:
7160350

Supplemental Content

Loading ...
Support Center